Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Fac 2006 plowe 1

380 views

Published on

Published in: Health & Medicine, Education
  • Be the first to comment

  • Be the first to like this

Fac 2006 plowe 1

  1. 1. ! "# $ ! %! & () *+) ! , * -..! ! ! !.
  2. 2. / 0 1 ! ! /##) ! !2*+3
  3. 3. ! , -
  4. 4. Current status:Pre-erythrocytic vaccines• RTS,S (U.S. Army & GlaxoSmithKline)–Recombinant CSP combined with hepatitisB surface antigen– Immune boosting agents (adjuvant)• AS02A: QS21, monophosporyl lipid A
  5. 5. 4 . / 54 . %!6.766 8 9! / :;</ 9=<! 8=3 1 6779. 677;
  6. 6. 8 6 : 9 ; > ? = @ 87 88 86 8: 89 8; 8>A B/8@ CD5 8 /5 8 / 889696! 8! !1# > D 8>99 ,E F*-. 8>@8 ,CF -. 8>@@, FD-. 8?77 ,DF -. 8?78 ,G F4-. 8?8> ,1F5-3 8@ B B.
  7. 7. 896 +# ! ! H 4 3 ) !4&! 4 . ,3 763-# ! ! G + C AH . ! 8 26 !// 889696
  8. 8. Bandiagara Malaria Project• Started 1997• University of Bamako / Faculty of Medicine– Malaria Research & Training Center• University of Maryland– Center for Vaccine Development• US National Institutes of Health• 20 scientific papers published• 2 malaria vaccine trials completed
  9. 9. 8 +8 +6 ! C8 98 4 ! + +) . 4 .
  10. 10. Malaria vaccine AMAMalaria vaccine AMA--11• P. falciparum apical membrane antigen-1• Expressed on merozoite surface,involved in erythrocyte invasion• Antibodies block invasion of merozoitesinto erythrocytes
  11. 11. 3 3 83 3 8 +! !
  12. 12. 3 33 3 8 +8 +8 68 >3 3 8 8 677>6 677?
  13. 13. ! ! "# !# !I I +!D3 "1 . !
  14. 14. / !1 4 .A!3 ;)3 ! !# A . ) . .
  15. 15. B3 0 !C 1 BD *J ! 3B4 A!1 41 !1 !1 A* !40 ! ! 3 ! C3 G !C3 ! &AD)K )3 D1 KH 43)4G K3* 3J 1G C3 13D)K 5)D)K A!D)K D783)=;:9>D)K ) ) 43) , -H 43)4 , -G C , &! -

×